

Alessandra Ferrario

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3148260/publications.pdf>

Version: 2024-02-01

28
papers

1,021
citations

567281

15
h-index

477307

29
g-index

30
all docs

30
docs citations

30
times ranked

1206
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of Palliative Care Among Commercially Insured Patients With Metastatic Cancer Between 2001 and 2016. <i>JCO Oncology Practice</i> , 2022, 18, e677-e687.	2.9	5
2	Intensity of End-of-Life Care in a Cohort of Commercially Insured Women With Metastatic Breast Cancer in the United States. <i>JCO Oncology Practice</i> , 2021, 17, e194-e203.	2.9	3
3	Strategies to achieve fairer prices for generic and biosimilar medicines. <i>BMJ, The</i> , 2020, 368, l5444.	6.0	31
4	Sales of anti-cancer medicines; China, Indonesia, Kazakhstan, Malaysia, Philippines and Thailand. <i>Bulletin of the World Health Organization</i> , 2020, 98, 467-474.	3.3	7
5	What are the volume and budget needs to provide chemotherapy to all children with acute lymphoblastic leukaemia in Thailand? Development and application of an estimation tool. <i>BMJ Open</i> , 2020, 10, e041901.	1.9	0
6	What are the volume and budget needs to provide chemotherapy to all children with acute lymphoblastic leukaemia in Thailand? Development and application of an estimation tool. <i>BMJ Open</i> , 2020, 10, e041901.	1.9	2
7	Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 251-261.	1.4	31
8	The need for comprehensive and multidisciplinary training in substandard and falsified medicines for pharmacists. <i>BMJ Global Health</i> , 2019, 4, e001681.	4.7	11
9	Global access to quality-assured medical products: the Oxford Statement and call to action. <i>The Lancet Global Health</i> , 2019, 7, e1609-e1611.	6.3	32
10	Time to Entry for New Cancer Medicines: From European Union – Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden. <i>Value in Health</i> , 2018, 21, 809-821.	0.3	20
11	Clinical and Financial Implications of Medicine Consumption Patterns at a Leading Referral Hospital in Kenya to Guide Future Planning of Care. <i>Frontiers in Pharmacology</i> , 2018, 9, 1348.	3.5	11
12	Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. <i>Frontiers in Public Health</i> , 2018, 6, 328.	2.7	102
13	Availability and affordability of medicines: towards an evidence base for routine assessment. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 759-761.	11.4	2
14	How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 307-321.	2.1	111
15	Managing Risk and Uncertainty in Health Technology Introduction: The Role of Managed Entry Agreements. <i>Global Policy</i> , 2017, 8, 84-92.	1.7	46
16	Determinants of utilisation differences for cancer medicines in Belgium, Scotland and Sweden. <i>European Journal of Health Economics</i> , 2017, 18, 1095-1105.	2.8	2
17	The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. <i>Pharmacoeconomics</i> , 2017, 35, 1271-1285.	3.3	94
18	Medicines dispensers' knowledge on the implementation of an artemisinin-based combination therapy policy for the treatment of uncomplicated malaria in Tanzania. <i>Journal of Pharmaceutical Health Services Research</i> , 2017, 8, 227-233.	0.6	11

#	ARTICLE	IF	CITATIONS
19	Strategic procurement and international collaboration to improve access to medicines. Bulletin of the World Health Organization, 2017, 95, 720-722.	3.3	9
20	Challenges in diabetes mellitus type 2 management in Nepal: a literature review. Global Health Action, 2016, 9, 31704.	1.9	35
21	Progress in increasing affordability of medicines for non-communicable diseases since the introduction of mandatory health insurance in the Republic of Moldova. Health Policy and Planning, 2016, 31, 793-800.	2.7	9
22	Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference. Journal of Pharmaceutical Policy and Practice, 2016, 9, 9.	2.4	16
23	Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Social Science and Medicine, 2015, 124, 39-47.	3.8	126
24	The economic burden of diabetes in India: a review of the literature. Globalization and Health, 2014, 10, 80.	4.9	108
25	An in-depth analysis of pharmaceutical regulation in the Republic of Moldova. Journal of Pharmaceutical Policy and Practice, 2014, 7, 4.	2.4	8
26	Diabetes in Algeria and challenges for health policy: a literature review of prevalence, cost, management and outcomes of diabetes and its complications. Globalization and Health, 2014, 10, 11.	4.9	29
27	Higher US Branded Drug Prices And Spending Compared To Other Countries May Stem Partly From Quick Uptake Of New Drugs. Health Affairs, 2013, 32, 753-761.	5.2	82
28	Dabigatran â€“ a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Frontiers in Pharmacology, 2013, 4, 39.	3.5	75